La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Egetis Therapeutics Gestione

Gestione criteri di controllo 2/4

Egetis Therapeutics' Il CEO è Nicklas Westerholm, nominato in Jun2017, ha un mandato di 7.17 anni. possiede direttamente 0.079% delle azioni della società, per un valore di SEK 1.20M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.2 anni e 5 anni.

Informazioni chiave

Nicklas Westerholm

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.2yrs
Proprietà del CEO	0.08%
Durata media del management	7.2yrs
Durata media del Consiglio di amministrazione	5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Aug 20

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26

Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

Mar 22

What Type Of Returns Would Egetis Therapeutics'(STO:EGTX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Feb 15

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Nicklas Westerholm rispetto agli utili di Egetis Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-SEK 319m
Mar 31 2024	n/a	n/a	-SEK 327m
Dec 31 2023	n/a	n/a	-SEK 327m
Sep 30 2023	n/a	n/a	-SEK 318m
Jun 30 2023	n/a	n/a	-SEK 286m
Mar 31 2023	n/a	n/a	-SEK 240m
Dec 31 2022	SEK 6m	SEK 3m	-SEK 194m
Sep 30 2022	n/a	n/a	-SEK 148m
Jun 30 2022	n/a	n/a	-SEK 113m
Mar 31 2022	n/a	n/a	-SEK 114m
Dec 31 2021	SEK 5m	SEK 3m	-SEK 104m
Sep 30 2021	n/a	n/a	-SEK 147m
Jun 30 2021	n/a	n/a	-SEK 153m
Mar 31 2021	n/a	n/a	-SEK 155m
Dec 31 2020	SEK 4m	SEK 2m	-SEK 178m
Sep 30 2020	n/a	n/a	-SEK 127m
Jun 30 2020	n/a	n/a	-SEK 134m
Mar 31 2020	n/a	n/a	-SEK 127m
Dec 31 2019	SEK 3m	SEK 2m	-SEK 61m
Sep 30 2019	n/a	n/a	-SEK 61m
Jun 30 2019	n/a	n/a	-SEK 48m
Mar 31 2019	n/a	n/a	-SEK 46m
Dec 31 2018	SEK 3m	SEK 2m	-SEK 85m
Sep 30 2018	n/a	n/a	-SEK 95m
Jun 30 2018	n/a	n/a	-SEK 103m
Mar 31 2018	n/a	n/a	-SEK 91m
Dec 31 2017	SEK 1m	SEK 1m	-SEK 88m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Nicklas sia ragionevole rispetto ad aziende di dimensioni simili nel mercato Swedish.

Compensazione vs guadagni: La retribuzione di Nicklas è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Nicklas Westerholm (48 yo)

7.2yrs

Mandato

SEK 5,900,000

Compensazione

Mr. Nicklas Westerholm has been the Chief Executive Officer of Egetis Therapeutics AB (publ) (formerly known as PledPharma AB (publ)) since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Nicklas Westerholm	Chief Executive Officer	7.2yrs	SEK 5.90m	0.079% SEK 1.3m
Torsten Almén	Founder	18.6yrs	Nessun dato	Nessun dato
Ingemar Lundström	Founder	18.6yrs	Nessun dato	Nessun dato
Louis Ignarro	Founder	18.6yrs	Nessun dato	Nessun dato
Heidi Brurok	Founder	18.6yrs	Nessun dato	Nessun dato
Rob Towart	Founder	18.6yrs	Nessun dato	Nessun dato
Yilmaz Mahshid	Chief Financial Officer	3.2yrs	Nessun dato	0.10% SEK 1.7m
Katayoun Welin-Berger	Vice President of Operations	1.4yrs	Nessun dato	Nessun dato
Jacques Näsström	Chief Scientific Officer	no data	SEK 655.00k	Nessun dato
Karl Hard	VP and Head of Investor Relations & Communication	2.5yrs	Nessun dato	Nessun dato
Laetitia Szaller	General Counsel & Head of Compliance	less than a year	Nessun dato	Nessun dato
Peter Verwaijen	Global Head of Marketing & Brand Strategy	2.3yrs	Nessun dato	Nessun dato

7.2yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di EGTX è esperto e expertise (durata media dell'incarico 7.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Dart	Member of Scientific Advisory Board	6.2yrs	Nessun dato	Nessun dato
Mats Blom	Chairman of the Board	3.3yrs	SEK 300.00k	1.07% SEK 17.9m
Behshad Sheldon	Independent Director	1.6yrs	Nessun dato	Nessun dato
Peder Walberg	Director	3.8yrs	Nessun dato	Nessun dato
Thomas Lonngren	Director	3.3yrs	SEK 600.00k	0.097% SEK 1.6m
Gunilla Osswald	Independent Director	7.6yrs	SEK 200.00k	0.014% SEK 228.8k
Elisabeth Svanberg	Independent Director	7.6yrs	SEK 200.00k	0.013% SEK 215.5k
Laura James	Member of Scientific Advisory Board	6.2yrs	Nessun dato	Nessun dato
James Dear	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

5.0yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EGTX sono considerati esperti (durata media dell'incarico 5 anni).

Egetis Therapeutics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Chief Executive Officer recently bought kr61k worth of stock

Independent Director recently bought kr206k worth of stock

Director recently bought kr992k worth of stock

Egetis Therapeutics AB (Publ) Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023

Egetis Therapeutics AB (publ), Annual General Meeting, Apr 27, 2023

Recent updates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 17% to kr11.90

Egetis Therapeutics AB (publ) to Report Fiscal Year 2024 Results on Feb 26, 2025

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Consensus revenue estimates increase by 13%

Egetis Therapeutics AB (publ) Announces Topline Results of the Phase 2 Triac Trial II with Emcitate (Tiratricol) for MCT8 Deficiency

Consensus revenue estimates decrease by 14%, EPS upgraded

Consensus EPS estimates upgraded to kr0.83 loss, revenue downgraded

Consensus revenue estimates increase by 25%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Share price stability

Price target increased by 11% to kr12.30

Egetis Therapeutics AB (publ) Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol (Emcitate) in the USA

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report Q1, 2024 Results on May 03, 2024

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Egetis Therapeutics AB (publ) Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency

Egetis Therapeutics AB (publ) Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency

Egetis Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 24, 2024

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (Publ) Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial

Chief Executive Officer recently bought kr61k worth of stock

Price target decreased by 8.3% to kr13.30

Forecast breakeven date pushed back to 2025

Independent Director recently bought kr206k worth of stock

Director recently bought kr992k worth of stock

Consensus revenue estimates decrease by 14%, EPS upgraded

Price target decreased by 7.4% to kr14.50

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

Egetis Terminates Discussions Regarding Potential Acquisition

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 13% to kr17.75

Forecast breakeven date pushed back to 2025

Consensus revenue estimates fall by 16%

Full year 2022 earnings released: kr1.00 loss per share (vs kr0.63 loss in FY 2021)

Egetis Therapeutics AB (Publ) Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023

Egetis Therapeutics AB (publ), Annual General Meeting, Apr 27, 2023

Consensus EPS estimates fall by 15%

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Egetis Therapeutics AB Submits Expanded Access Program for Emcitate® in the USA

Egetis Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Egetis Therapeutics AB (publ) Receives Positive Opinion on Orphan Designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure

Forecast breakeven date pushed back to 2024

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

No longer forecast to breakeven

Egetis Therapeutics AB (Publ) Announces Executive Changes

Price target decreased to kr9.00

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Egetis Therapeutics AB (Publ) Announces That the Recruitment Target Has Been Met in the Emcitate® Triac Trial II Study

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) Secures Conditional Acceptance for Emcitate® as Brand Name in the US

Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?

Egetis Therapeutics AB (publ) Concludes Demonstrating Treatment Effects on T3 Levels in Mct8-Deficiency Could Provide Basis for Marketing Approval for Emcitate® in the Us

Egetis Therapeutics AB (Publ) Gets Notice of Intent to Grant for a New European Patent for a Combination Therapy with Aladote

Egetis Therapeutics AB (publ) Intends to Submit Marketing Authorisation Application for Emcitate® to the European Medicines Agency Based on Existing Clinical Data

Chief Executive Officer recently bought kr299k worth of stock

Third quarter 2021 earnings released: kr0.14 loss per share (vs kr0.46 loss in 3Q 2020)

Chief Financial Officer recently bought kr210k worth of stock